Trenton, September 18, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement concerning today’s White House announcement on Medicaid’s GENEROUS drug pricing program:
“As we’ve long stated, New Jersey’s life sciences remain committed to lowering costs for patients across America. Individual voluntary agreements between government and innovative companies – as opposed to mandatory, across-the-board government price controls – take into account the billions of dollars and decades that go into researching, discovering, and manufacturing new, life-saving treatments and cures.”
Buteas continued, “New Jersey’s life sciences companies work with policymakers in Washington and Trenton to find responsible ways to lower costs while continuing to invest in American innovation and tomorrow’s cutting-edge medical advances.”
Buteas concluded, “We are proud to be known as the ‘Medicine Chest of the World,’ and we will continue finding new ways to save lives and lower costs in ways that protect patients and New Jersey’s global leadership in medical innovation.”